A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The primary purpose of the study is to assess the safety, tolerability, and anti-tumor activity of HER3-DXd and T-DXd in the combination dosing regimens in participants with hormone receptor positive, HER2-low or HER2-ultralow, unresectable, or metastatic breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak piersi, który rozprzestrzenił się lub nie można go usunąć operacyjnie.
- •Rak piersi dodatni pod względem receptorów hormonalnych (ER lub PgR).
- •Rak piersi określony jako HER2-niski (IHC 2+/ISH- lub IHC 1+) lub HER2-bardzo niski (IHC 0 z jakimkolwiek zabarwieniem błony komórkowej u 0-10% komórek rakowych).
- •Dostępna próbka tkanki guza do badań (z biopsji sprzed leczenia lub nowo pobranej).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (72)
Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute
Los Angeles, United States
Stanford Medicine Cancer Center
Stanford, United States
University of Colorado Denver - School of Medicine - Anschutz Medical Campus
Aurora, United States
Yale University School of Medicine - Yale Cancer Center
New Haven, United States
Massachusetts General Hospital
Boston, United States
Dana-Farber Cancer Institute
Boston, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, United States
Compass Oncology - Rose Quarter Cancer Center
Portland, United States
The West Cancer Center
Memphis, United States
SCRI Oncology Partners
Nashville, United States
University of Texas Southwestern
Dallas, United States
Virginia Oncology Associates
Norfolk, United States
Cliniques Universitaires Saint-Luc
Brussels, Belgium
UZ Leuven
Leuven, Belgium
Centre Francois Baclesse
Caen, France
Centre Georges Francois Leclerc
Dijon, France
Centre Oscar Lambret
Lille, France
Centre Leon Berard
Lyon, France
Institut Paoli-Calmettes
Marseille, France
ICM - Institut Regional du Cancer de Montpellier
Montpellier, France
Centre Antoine-Lacassagne
Nice, France
CHU de Nimes
Nîmes, France
Institut Curie
Paris, France
Centre Eugene Marquis
Rennes, France
Institut de Cancerologie de l'Ouest - site St-Herblain
Saint-Herblain, France
Oncopole Claudius Regaud
Toulouse, France
Institut de Cancerologie de Lorraine - Alexis Vautrin
Vandœuvre-lès-Nancy, France
Institut Gustave Roussy
Villejuif, France
Centro Riferimento Oncologico - Aviano
Aviano, Italy
IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l.
Meldola, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Istituto Europeo di Oncologia
Milan, Italy
Fondazione IRCCS San Gerardo dei Tintori
Monza, Italy
Istituto Oncologico Veneto-I.R.C.C.S. - Ospedale Busonera
Padova, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Italy
National Cancer Center Hospital East
Kashiwa, Japan
Tokai University Hospital
Isehara, Japan
Kanagawa Cancer Center
Yokohama, Japan
Kansai Medical University Hospital
Hirakata, Japan
National Cancer Center Hospital
Chuo-ku, Japan
Cancer Institute Hospital of JFCR
Koto-ku, Japan
Showa Medical University Hospital
Shinagawa-ku, Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
Fukushima Medical University Hospital
Fukushima, Japan
Osaka International Cancer Institute
Osaka, Japan
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Institut Catala d'Oncologia - Badalona
Badalona, Spain
NEXT Oncology Barcelona
Barcelona, Spain
Hospital Universitari Quiron Dexeus Barcelona
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Clinic Barcelona
Barcelona, Spain
Hospital Universitario San Cecilio
Granada, Spain
Hospital Beata Maria Ana
Madrid, Spain
Clinica Universidad de Navarra - Madrid
Madrid, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
Madrid, Spain
Hospital Regional Universitario de Malaga
Málaga, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Clinica Universidad de Navarra - Pamplona
Pamplona, Spain
NEXT Oncology Madrid
Pozuelo de Alarcón, Spain
Hospital Universitario de Canarias
Santa Cruz de Tenerife, Spain
Hospital Clinico Universitario de Santiago
Santiago de Compostela, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Taichung Veterans General Hospital
Taichung, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Koo Foundation Sun Yat-Sen Cancer Center
Taipei, Taiwan
Trial contact
Daiichi Sankyo Contact for Clinical Trial Information
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/2/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.